Literature DB >> 28003275

TP53 Mutations in Hypodiploid Acute Lymphoblastic Leukemia.

Evan Q Comeaux1, Charles G Mullighan1.   

Abstract

Acute lymphoblastic leukemia (ALL) is an aggressive neoplasm of B- or T-lymphoid progenitors and is the commonest childhood tumor. ALL comprises multiple subtypes characterized by distinct genetic alterations, with stereotyped patterns of aneuploidy present in many cases. Although alterations of TP53 are common in many tumors, they are infrequent in ALL, with the exception of two ALL subtypes associated with poor outcome: relapsed disease and ALL with hypodiploidy. TP53 alterations are present in almost all cases of ALL with low hypodiploidy and are associated with alterations of the lymphoid transcription factor IKZF2 and the tumor-suppressor gene loci CDKN2A and CDKN2B. Remarkably, more than half of TP53 mutations in low-hypodiploid ALL in children are present in nontumor cells, indicating that low-hypodiploid ALL is a manifestation of Li-Fraumeni syndrome. These findings have profound implications for our understanding of the genetic pathogenesis of hypodiploid ALL, suggesting that alteration of TP53 function may promote the distinctive aneuploidy characteristic of hypodiploid ALL. Moreover, the identification of hypodiploidy mandates offering testing for TP53 mutational status to patients and their relatives, with appropriate counseling and disease surveillance.
Copyright © 2017 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28003275      PMCID: PMC5334249          DOI: 10.1101/cshperspect.a026286

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  17 in total

Review 1.  The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition.

Authors:  Rashmi Kanagal-Shamanna
Journal:  Curr Hematol Malig Rep       Date:  2021-05-24       Impact factor: 3.952

2.  TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.

Authors:  Maoxiang Qian; Xueyuan Cao; Meenakshi Devidas; Wenjian Yang; Cheng Cheng; Yunfeng Dai; Andrew Carroll; Nyla A Heerema; Hui Zhang; Takaya Moriyama; Julie M Gastier-Foster; Heng Xu; Elizabeth Raetz; Eric Larsen; Naomi Winick; W Paul Bowman; Paul L Martin; Elaine R Mardis; Robert Fulton; Gerard Zambetti; Michael Borowitz; Brent Wood; Kim E Nichols; William L Carroll; Ching-Hon Pui; Charles G Mullighan; William E Evans; Stephen P Hunger; Mary V Relling; Mignon L Loh; Jun J Yang
Journal:  J Clin Oncol       Date:  2018-01-04       Impact factor: 44.544

3.  Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets.

Authors:  Jessica I Hoell; Sebastian Ginzel; Michaela Kuhlen; Andreas Kloetgen; Michael Gombert; Ute Fischer; Daniel Hein; Salih Demir; Martin Stanulla; Martin Schrappe; Udo Zur Stadt; Peter Bader; Florian Babor; Friedhelm Schuster; Brigitte Strahm; Julia Alten; Anja Moericke; Gabriele Escherich; Arend von Stackelberg; Ralf Thiele; Alice C McHardy; Christina Peters; Beat Bornhauser; Jean-Pierre Bourquin; Stefan Krause; Juergen Enczmann; Lüder Hinrich Meyer; Cornelia Eckert; Arndt Borkhardt; Roland Meisel
Journal:  Blood Adv       Date:  2019-10-22

4.  Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia.

Authors:  Frank N van Leeuwen
Journal:  Haematologica       Date:  2020-01       Impact factor: 9.941

Review 5.  Molecular markers in ALL: Clinical implications.

Authors:  Shunsuke Kimura; Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2020-06-07       Impact factor: 3.020

Review 6.  Pediatric leukemia susceptibility disorders: manifestations and management.

Authors:  Lisa J McReynolds; Sharon A Savage
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

7.  Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.

Authors:  Ernesto Diaz-Flores; Evan Q Comeaux; Kailyn L Kim; Ella Melnik; Kyle Beckman; Kara L Davis; Kevin Wu; Jon Akutagawa; Olga Bridges; Roberta Marino; Margo Wohlfeil; Benjamin S Braun; Charles G Mullighan; Mignon L Loh
Journal:  Cancer Res       Date:  2019-03-12       Impact factor: 12.701

8.  Association of TP53 gene polymorphisms with the risk of acute lymphoblastic leukemia in Moroccan children.

Authors:  Hanaa Skhoun; Mohammed Khattab; Aziza Belkhayat; Zahra Takki Chebihi; Youssef Bakri; Nadia Dakka; Jamila El Baghdadi
Journal:  Mol Biol Rep       Date:  2022-06-15       Impact factor: 2.742

Review 9.  New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update.

Authors:  Adrián Montaño; Maribel Forero-Castro; Darnel Marchena-Mendoza; Rocío Benito; Jesús María Hernández-Rivas
Journal:  Cancers (Basel)       Date:  2018-04-07       Impact factor: 6.639

10.  Hypodiploidy in a pediatric patient of T-cell acute lymphoblastic leukemia: a case report.

Authors:  Martyna Stefaniak; Gabriela Ręka; Joanna Zawitkowska; Monika Lejman
Journal:  BMC Med Genomics       Date:  2021-07-03       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.